In a major shift for women’s health policy, the US Food and Drug Administration has approved changes to the safety labelling on several hormone replacement therapy (HRT) medications used to treat menopausal symptoms, eliminating the most prominent warning about potential risks and aligning labels more closely with current scientific evidence.
The update, released on February 12, 2026, affects the ‘boxed warning’ – the agency’s strongest safety alert – on six widely prescribed menopausal hormone therapy products. Language about potential risks of cardiovascular disease, breast cancer and probable dementia has been removed from these labels, following a comprehensive review of evidence and risk-benefit considerations.
The therapies involved span multiple product categories, including systemic oestrogen-alone, systemic progestogen-alone, combined oestrogen-progestogen treatments, and topical vaginal oestrogen options. All had carried boxed warnings that, in some cases, reduced prescribing and discouraged appropriate use by clinicians and patients alike.
FDA Commissioner Marty Makary, MD, MPH, said the change reflects updated understanding of hormone therapy and the importance of evidence-based labels. He noted that many women experience significant quality-of-life benefits from hormone therapy, including relief from hot flashes, night sweats and other vasomotor symptoms that accompany menopause.
Reversing a long-standing legacy of misinterpreted data
The decision stems from a long-running reassessment of HRT that began in late 2025, after the agency conducted an extensive review of scientific literature, convened an expert panel and solicited public comment. Data from randomised studies indicate that women who start hormone therapy within ten years of the onset of menopause – generally before age 60 – may experience reduced all-cause mortality and fewer bone fractures.
Advocates of the change argue that the original boxed warnings, which date back to the early 2000s and were based in part on findings from the Women’s Health Initiative, overestimated long-term risks for contemporary hormone therapy formulations and may have unduly deterred appropriate treatment.
The FDA’s action is expected to prompt broader discussion within the medical community as clinicians and patients navigate menopausal care. While the removal of the boxed warnings is poised to increase confidence in hormone therapy, ongoing research and clinical judgment will remain central to its safe and effective use.
In Australia, the conversation around menopause is also undergoing rapid recalibration. The Australian Senate’s Community Affairs References Committee tabled a landmark 169-page report in September 2024 confirming that under-diagnosis, misinformation and limited access to treatment were costing women their health, careers and wellbeing.
The bipartisan inquiry made 25 sweeping recommendations spanning clinical education, MBS reform, hormone therapy access, advertising oversight and national awareness campaigns. Since then, the Federal Government has committed significant funding toward research, guidelines and public education. As awareness grows, women are asking more informed questions of every health professional they encounter, including in aesthetic practice.
In this context, the FDA’s decision to remove long-standing boxed warnings resonates well beyond the United States. It reflects a broader international reassessment of menopause care, where policy, prescribing guidance and public understanding are increasingly being aligned with contemporary evidence rather than legacy interpretations of early 2000s data. As Australia advances its own menopause reform agenda, regulatory clarity and evidence-based risk communication will be central to ensuring women have informed access to appropriate therapy.
